Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
6 drugs in development
By Therapeutic Area
top 4
R&D Momentum
63/100
Pipeline Velocity
39/100
Trial Completion Rate
91/100
Pipeline Concentration
28/100
Pipeline Freshness
56/100
Strategic Signals
Activity
Last 14 days
Protocol for Developing and Validating a Multimodal Brain Monitoring-Based Prognostic Model for Neurocritical Patients: A Prospective, Observational, Multicenter Cohort Study
A Retrospective, Multicenter Study to Develop and Validate a Non-Invasive Artificial Intelligence Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT, With Pathologically Confirmed Diagnosis as the Reference Standard
Posterior Transforaminal Debridement and Fusion Without Costotransversectomy for Thoracic Pyogenic Vertebral Osteomyelitis: A Randomized Controlled Trial Emphasizing Posterior Ligamentous Complex Preservation
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)